Posted by psychobot5000 on June 28, 2012, at 18:46:48
In reply to Re: D2 (D3) agonists' capacity to flatten affect » psychobot5000, posted by SLS on June 28, 2012, at 14:07:16
> > I am unsure whether there might be a dosing regimen of agents with D3 (a 'D2-like' receptor) that might prevent or supercede this phenomenon, i.e. perhaps with higher doses.
> Very possibly. The dosage-response curve of apomorphine, comprising sedation followed by hyperlocomotion, is an example of this.
> Aripiprazole and cariprazine are partial D2/D3 agonists that seem not to have a pervasive effect of the flattening of mood at low dosages. Infrequently, these drugs can blunt cognition and affect at high dosages.
> - Scott
Hmm. This is useful--though aripiprazole unfortunately blunted my cognition in a big way even on a small dose. ...I've heard of that effect wearing off, though.
Do you know of any links/papers that might support these ideas, Scott, i.e. something I could take to my doc to show there's good reason to do a trial?